SCHEMBL2390178

SCHEMBL2390178

Oc1ccc(OCc2ccccc2)cc1I

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.59
CYP1A2 P05177 1/20 0.59
PTGS1 P23219 1/20 0.59
SLC6A2 P23975 1/20 0.59
CYP2C19 P33261 1/20 0.59
PTGS2 P35354 1/20 0.59
SLC6A3 Q01959 1/20 0.59
HIF1A Q16665 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
MAOB P27338 8/20 0.56
ALOX5 P09917 1/20 0.56
MCL1 Q07820 1/20 0.52
APP P05067 2/20 0.50
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
MAOA P21397 2/20 0.49
NR4A2 P43354 2/20 0.49
MAPT P10636 2/20 0.49
NR4A1 P22736 1/20 0.49
NR4A3 Q92570 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15968723 0.88 LMNA (0.61) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL8599201 0.85 LMNA (0.68) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL2096058 0.81 LMNA (0.61) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL1734928 0.79 LMNA (0.59) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL2875005 0.79 ALOX5 (0.56) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL2900304 0.79 LMNA (0.59) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL20456375 0.79 MAOB (0.57) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL1532839 0.79 LMNA (0.59) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL7879365 0.79 ALOX5 (0.56) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL7779413 0.79 LMNA (0.59) LMNACYP1A2PTGS1SLC6A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE42700-E1 Induction of apoptosis in cancer cells SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2011-09-13 US disclosed
CN-100348569-C Induction of apoptosis in cancer cells BURNHAM INST (US) 2007-11-14 CN disclosed
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
CN-1659130-A Induction of apoptosis in cancer cells BURNHAM INST (US) 2005-08-24 CN disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 LMNA 341/4885CYP1A2 3399/4885PTGS1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.